Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

A recent study revealed that weight loss drugs, GLP-1s, including Ozempic and Zepbound, may help in treating several chronic ...

Six months ago, I took a leap into the unknown, writes DONAL MACINTYRE. After tipping the scales the other way, here I reveal ...

As the popularity of the type-2 diabetes drugs have risen, researcher have been looking into different aspects of it to ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

WEIGHT loss jabs could help control asthma symptoms in obese people, a study suggests – and it’s not just about losing weight ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

Common medicines, including diabetes, cancer, and antiviral drugs, may offer new hope in slowing dementia. UK researchers, including a team from the University of Cambridge, have uncovered strong ...

GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric emptying - also have a range of other benefits.